

## Development of an Isotope-Dilution Flow-Injection Electrospray/Mass Spectrometric Method for the Accurate Determination of Glucosamine in Pharmaceutical Formulation

Guinam Kim,<sup>†</sup> Byungjoo Kim,<sup>\*</sup> Seonghee Ahn, Euijin Hwang, and Yongseong Kim<sup>†</sup>

Division of Metrology for Quality Life, Korea Research Institute of Standards and Science, Yuseong, Daejeon 305-600, Korea. \*E-mail: byungjoo@kriss.re.kr

<sup>†</sup>Department of Chemistry, Kyungnam University, Masan, Kyungnam 631-701, Korea  
Received October 7, 2008, Accepted December 18, 2008

An isotope-dilution flow-injection electrospray/mass spectrometric method was developed for the accurate determination of glucosamine contents in pharmaceutical formulations. Samples were extracted by methanol. After spiking glucosamine-1-<sup>13</sup>C<sub>1</sub> as an internal standard, the extracts were then analyzed by flow-injection ESI/MS in a selected ion monitoring (SIM) mode to detect [M+H]<sup>+</sup> ions of the analyte and its isotope analogue at m/z 180 and m/z 181, respectively. Confirmatory measurements were made by selectively monitoring the collisionally induced dissociation channels of m/z 180 → m/z 72 and m/z 181 → 73, respectively, to test the possibility of bias in the SIM method due to matrix interferences, but any significant bias in the SIM mode was not observed. Repeatability and reproducibility studies showed that the flow-injection ESI/MS method is a reliable and reproducible method which can provide a typical method precision of 1.0 %. Other results for the method validation are reported.

**Key Words:** Glucosamine. Nutritional supplement. Flow-injection ID-ESI/MS. Method validation

### Introduction

Glucosamine is a natural amine sugar extracted from the chitin in Crustaceans such as shrimps and crabs. As researches have shown that glucosamine is efficacious in the treatment of degenerative joint diseases,<sup>1,2</sup> glucosamine is currently one of the popular dietary supplements. As numerous glucosamine products are marketed as nutritional supplements with pharmaceutical formulations for the prevention and treatment of osteoarthritis and degenerative joint diseases,<sup>3,4</sup> the glucosamine contents in those products should be labeled on the products in accordance with food labeling laws and are tested by regulatory bodies and contracted laboratories for consumer protection and safety. Therefore, a definitive method for the accurate determination of glucosamine contents is required as a reference method to harmonize the analytical results.

High performance liquid chromatographic (HPLC) methods have been used for the analysis of glucosamine in dosage forms.<sup>2,5,6</sup> However, typical UV/VIS detectors have shown limitation because glucosamine does not contain a chromophore to absorb UV/VIS light. Therefore, refractive index detectors have been employed for the HPLC analysis of glucosamine.<sup>7,8</sup> In addition to the detection difficulty, a relatively cumbersome normal phase LC separation is required for the direct analysis of glucosamine in pharmaceutical products.<sup>2,5-8</sup> Pre-column derivatization has been employed to overcome the detection difficulty and/or to adopt a reverse phase LC separation.<sup>9,11</sup> Recently, a normal phase LC separation with ESI/MS detection method has been employed for the direct determination of glucosamine in human plasma.<sup>12</sup> The mass spectrometric detection has been proved to be more specific and sensitive than those spectroscopic detections.

In this paper, a simple method is developed based on a flow-injection ESI/MS with isotope dilution techniques as a

candidate reference method for the accurate determination of glucosamine contents in nutritional supplements in dosage forms. In this method, a flow-injection stage substitute the usual LC separation step preceding the ESI/MS detection as the high selectivity of the mass spectrometric detection is expected to eliminate interferences from pharmaceutical formulations whose matrix are relatively simple. Glucosamine-1-<sup>13</sup>C is used as an internal standard for employing isotope dilution techniques to improve the accuracy of analytical results. Also, adopting the isotope labeled analogue of the target analyte as an internal standards is expected to eliminate the possible bias due to ion suppression/enhancement by matrix interference in the ionization processes. For the validation of the method, the results from the flow-injection ESI/MS in the SIM mode chosen as a primary detection mode was compared with those in the SRM mode used as a confirmatory detection mode. The repeatability and reproducibility of the method were also tested to evaluate the metrological quality of the method.

### Experimental

**Materials.** D-Glucosamine hydrochloride (99+%) from Sigma-Aldrich (St. Louis, MO, USA) was used as a primary reference material without further purification. D-glucosamine-1-<sup>13</sup>C was also purchased from Sigma-Aldrich. HPLC grade organic solvents (methanol and acetonitrile) were obtained from Burdick and Jackson (Muskegon, MI, USA). Filter cartridges (PURDISC NYL 25 FILTER 25 mm 0.45 μm) were purchased from Whatman (Clifton, NJ, USA). Nutritional supplements in tablet or capsule forms from several manufacturers were purchased from local markets and were used as samples.

**Calibration Standard Solutions.** The standard solution used in this study was prepared and verified according to a pro-

cedure maintained in our laboratory,<sup>13-16</sup> the national metrology institute of Korea. The brief description of the procedure is as follows. Four glucosamine standard solutions of a 100 mg/kg level in methanol were gravimetrically prepared independently. A glucosamine-1-<sup>13</sup>C standard solution of a 100 mg/kg level was prepared in the same way. For each of the four glucosamine standard solutions, two isotope ratio standard solutions with 1:1 isotope ratio were prepared by gravimetrically mixing with the glucosamine-1-<sup>13</sup>C standard solution. We cross-checked the isotope ratio standard solutions to test the self-consistencies of the standard solutions and the isotope ratio standard solutions by using the flow-injection ESI/MS method established in this study. Based on the cross-check results, an isotope ratio standard solution was selected and used in sample analysis.

**Sample Preparation and Clean-up.** Tablet samples or contents in capsules were homogenized by grinding with a laboratory mill prior to subsampling. 0.1 g of homogenized sample was weighed into a 120 mL glass bottle and 100 mL of methanol was added into it. Though water or water/acetonitrile (50/50) was used in previous studies as extraction solvents,<sup>2,7</sup> methanol was chosen as an extraction solvent in this study after comparison of extraction efficiencies of the three solvents. The exact amounts of sample and extraction solvent were determined by weighing the bottle before and after addition of each of them. The bottle was capped tightly, and was subject to shaking for complete mixing, sonification for 1 hour in a water bath at room temperature, and sonification for 1 hour at 50 °C. 0.5 mL of the supernatant of sample extract was pipetted into a vial. An appropriate amount of the glucosamine-1-<sup>13</sup>C standard solution was spiked to the vial so that the ratio of glucosamine to glucosamine-1-<sup>13</sup>C was close to 1.0. The content of the vial was well mixed and passed through a filter cartridge (PURDISCNYL 25 FILTER 25 mm 0.45 μm). A portion of the filtered extract was then diluted with methanol to a level which is convenient for ESI/MS analysis (10 mg/kg in this study). The same dilution was done for the isotope ratio standard solution.

**Flow-Injection ESI/MS Analysis.** The LC /tandem MS used in this study was an API 2000 mass spectrometer from Applied Biosystems (Foster City, CA, USA) combined with an 1100 Series LC system from Agilent Technologies (Palo Alto, CA, USA) through its electrospray ionization interface. We adopted the mass spectrometer with a triple quadrupole mass analyzer as analyzers of this type are known to provide a better quantitative performance compared to ion-trap type or time-of-flight type analyzers. In this study, 100% methanol mobile phase stream from the LC pump at the flow rate of 0.3 mL/min. was connected to the ESI interface without a LC column. Sample extracts and calibration standard mixtures were injected into the mobile phase stream in 10 μL volume units by using an autosampler equipped in the LC system. The mass spectrometer was operated in the positive ion mode. For the principal measurement, MS was operated in the selected ion monitoring (SIM) mode for monitoring the [M+H]<sup>+</sup> ions of glucosamine and glucosamine-1-<sup>13</sup>C at m/z 180 and 181, respectively. To test bias due to matrix interferences, confirmatory measurements was done in the selected reaction monitoring (SRM) mode by detecting the collisionally induced

dissociation (CID) channels of the [M+H]<sup>+</sup> ions to [C<sub>3</sub>H<sub>6</sub>NO]<sup>+</sup> at m/z 180 → m/z 72 and m/z 181 → 73, respectively. For the SRM mode, the collision cell, the second quadrupole of the mass spectrometer, was filled with nitrogen gas at a pressure of ~ 0.2 Pa (~ 2.0 × 10<sup>-3</sup> mbar) and the collision energy was adjusted to 27 eV.


## Results and Discussion

**Flow Injection ESI/MS.** Full-scan mass spectra of glucosamine and glucosamine-1-<sup>13</sup>C were dominated by the protonated molecular ions [M+H]<sup>+</sup> at m/z 180 and 181, respectively, and the most intense peak in the CID product ion mass spectra of the [M+H]<sup>+</sup> ions were at m/z 72 and 73, respectively. These results are in a good agreement with a previous study.<sup>12</sup> In this study, the [M+H]<sup>+</sup> ions at m/z 180 and 181 were selected for the mass spectrometric detection of glucosamine and glucosamine-1-<sup>13</sup>C, respectively. The CID channels of m/z 180 → m/z 72 and m/z 181 → 73 were chosen for the confirmatory measurements in the SRM mode.

Figure 1 shows signal profiles of MS in the SIM mode obtained by flow-injection of glucosamine standard solutions at various concentrations. Each signal profile has a peak which arises rapidly from 0.12 minute to its maximum at 0.22 minute and decrease with a little tailing to the background level within 1.0 minute. The inset of the graph is a calibration curve for the peak area versus the concentration of glucosamine. The calibration curve shows a very good linearity, indicating that the flow-injection ESI/MS in the SIM mode can be used for the quantitative analysis of glucosamine. A similar linearity was also observed when MS signals were detected in the SRM mode.


Figure 2 shows the typical profiles of SIM and SRM signals of glucosamine and glucosamine-1-<sup>13</sup>C from an extract of a glucosamine product obtained from a local market. The profiles are similar to those obtained from standard solutions as shown in Figure 1.

To test the performance of the flow-injection ESI/MS detection for the IDMS analysis of glucosamine, the standard deviation of the area ratio of glucosamine and glucosamine-1-<sup>13</sup>C




**Figure 1.** Glucosamine signal profiles of ESI/MS in the SIM mode at m/z 180 obtained by flow-injection of glucosamine standard solutions with a series of concentrations. The inset of the graph is a calibration curve of the peak area versus the concentration of glucosamine.

## a) SIM mode detection



## b) SRM mode detection



**Figure 2.** Typical profiles of MS-SIM and MS-SRM signals of glucosamine and glucosamine-1-<sup>13</sup>C from an extract of a glucosamine product obtained from a local market.

was evaluated from multiple runs of sample extracts and calibration standard mixtures. The relative standard deviation of the area ratio from both SIM and SRM modes was typically around 0.8 % for both sample extracts and calibration standard mixtures. The results indicate that the flow-injection ESI/MS method with isotope dilution techniques can provide a high metrological quality in glucosamine measurements. Therefore, we have chosen the isotope-dilution flow-injection ESI/MS in the SIM mode as a candidate reference method for the analysis of glucosamine in pharmaceutical formulations.

**Method Validation and Analytical Quality Check.** We carefully evaluated if the flow-injection ESI/MS in the SIM mode, combined with isotope dilution techniques, has an adequate quality as a reference method that can be used in national metrology institutes. As no matrix CRM with a certified value for glucosamine is available yet to our knowledge, "validation by using well-characterized standard or published methods" is not applicable. Therefore, careful evaluations of performance parameters of the method including repeatability, reproducibility, and sources of uncertainty are required.

**Repeatability and Reproducibility.** To test the repeatability and the reproducibility of the LC/MS method, a homogenized sample was prepared by using a procedure maintained in our laboratory for the preparation of certified reference materials. In brief, more than 200 g of glucosamine tablets, from a single batch of a manufacturer and with an adequate level of glu-

**Table 1.** Measurement results of glucosamine in a homogenized pharmaceutical product by the flow-injection ESI/MS in the SIM mode in three different time periods

Subsample No.	Measurement Results (% in g/g)
#1	54.2
#2	54.1
#3	54.6
#4	54.4
Average	54.3
Standard deviation	0.2 (0.4 rel% <sup>b</sup> )
Expanded uncertainty <sup>a</sup>	1.2 (2.3 rel% <sup>b</sup> )
-----	
#1	54.4
#2	53.3
#3	54.3
#4	54.5
Average	54.1
Standard deviation	0.5 (1.0 rel% <sup>b</sup> )
Expanded uncertainty <sup>a</sup>	1.7 (3.1 rel% <sup>b</sup> )
-----	
#1	54.0
#2	54.2
#3	54.7
#4	54.8
Average	54.4
Standard deviation	0.4 (0.7 rel% <sup>b</sup> )
Expanded uncertainty <sup>a</sup>	1.8 (3.3 rel% <sup>b</sup> )
-----	
Average	54.3
Standard deviation among period	0.14 (0.35 rel% <sup>b</sup> )

<sup>a</sup>The expanded uncertainties are with a level of confidence of 95%. <sup>b</sup>The unit "rel%" indicates the relative percentage of the standard deviation or the uncertainty of the value in front of the parenthesis in comparison with the corresponding mean value.

cosamine, was homogenized by pulverization, sieving for selecting particles below 250 μm and V-mixing. The homogenized sample was bottled into amber jars in 20 g unit, which was stored at 4 °C before use.

To test the repeatability of the candidate reference method, multiple subsamples were analyzed in a single period. To test reproducibility of the methods, the same repeatability test on the homogenized sample was carried out after a reasonable time interval of weeks to months. For the repeatability test in each time period, a new set of multiple standard solutions were prepared and used after verification by the self-consistency test described in the experimental section. Table 1 lists the measurement results obtained at three different time periods.

The relative standard deviation of the results obtained from the SIM mode within a time period is less than 1.0 % of the corresponding mean values, indicating that the methods has excellent repeatability. Results from the SRM mode also showed the similar level of repeatability

The relative standard deviation of the means of the three different time periods was 0.14 % for the SIM mode, which is smaller than the repeatability of within periods, indicating that the flow-injection ESI/MS method in the SIM mode has the high degree of reproducibility.

**Limit of Quantification (LOQ).** The limit of detection (LOD)

and LOQ, measured as the concentrations corresponding to signal-to noise ratio of 3:1 and 10:1, respectively, are 0.1 and 0.3 mg/kg in the extraction solvent. Therefore, the LOD and LOQ of this method are estimated to be 0.1 and 0.3 % mass fraction of glucosamine in solid samples.

**Confirmatory Measurements.** The homogenized sample and additional 7 glucosamine products in pharmaceutical formulation, which were all from different manufacturers and purchased from local markets, were analyzed by the flow-injection ESI/MS in the SIM mode and the SRM mode. The results from the two detection modes are listed in Table 2. The results from the principal measurements in the SIM mode and the confirmatory measurements in the SRM mode agree within their uncertainties. The results indicate that the SIM mode measurements do not show a significant bias in comparison with the SRM measurement which provide one more stage of selectivity. Therefore, the possibility of matrix interferences

**Table 2.** Measurement results of glucosamine in commercial pharmaceutical formulas by the flow-injection ESI/MS in the SIM and SRM modes

Products	Glucosamine Contents (% in g/g) <sup>a</sup>		Difference (% in g/g)
	SIM mode	SRM mode	
Sample in table 1	54.3 ± 0.2	53.3 ± 1.3	1.0
Product A	53.3 ± 0.7	54.7 ± 0.9	1.3
Product B	24.3 ± 0.8	23.1 ± 0.6	1.2
Product C	46.5 ± 0.4	47.0 ± 0.8	0.5
Product D	28.7 ± 0.7	29.8 ± 0.5	1.2
Product E	53.4 ± 1.3	53.6 ± 2.6	0.2
Product F	83.1 ± 3.5	82.8 ± 4.0	0.3

<sup>a</sup>The values following “±” are the expanded uncertainties of the preceding values with a level of confidence of 95 %.

from pharmaceutical formulations is very small in the SIM mode measurement.

**Test of Other Isomeric Interferences.** The method developed in this study could not differentiate glucosamine from its isomeric compounds, such as galactosamine and mannosamine as their molecular ions,  $[M + H]^+$ , are at the same position of  $m/z$  180. However, the two isomeric compounds are not expected to be present in most of commercial products as they are produced based on glucosamine sulfate or glucosamine hydrochloride extracted from the chitin in Crustaceans such as shrimps and crabs and the two isomeric compounds are not included in the extracted raw material. We analyzed most of glucosamine products available in the local market as shown in Table 2 with a LC/ESI/MS method established in our laboratory to test the possibility of the co-presence of those isomeric compounds. A manuscript for details of this method is under preparation. In brief, the three isomeric compounds were separated with a normal phase LC column (Phenomenex Luna 5 $\mu$ m NH<sub>2</sub>, 150 mm length 4.6 mm I.D.) with isocratic mobile phase (10% of 20 mM Ammonium acetate buffer solution with pH 10.5 and 90 % of acetonitrile) at 1.0 mL/min. ESI/MS as described in the text was used for the detection of LC eluent. Galactosamine, and mannosamine were not detected in all products tested in this study. Therefore, the flow-injection ESI/MS method can be applied to determine glucosamine in nutritional supplements which used glucosamine extracted from the chitin in Crustaceans as a raw material.

**Uncertainty Sources.** As a full discussion of the measurement uncertainty is beyond the scope of this article, only a brief description is given. Details on uncertainties sources and their evaluation methods in typical IDMS methods were described in previous articles published from this laboratory.<sup>13-16</sup> Uncertainty sources of the results from the flow-injection ESI/MS

**Table 3.** Uncertainty sources in the ID-flow-injection ESI/MS for the determination of glucosamine in pharmaceutical formulation

Uncertainty Components	Sources (Evaluation Methods)	Typical value (Relative %)	Relation with Repeatability and Reproducibility <sup>a</sup>
Glucosamine standard solution	Purity of the reference material (from manufacturer's certificate)	0.1 %	Systematic uncertainty
	Gravimetric preparation (from cross-check of independent sets of calibration solutions)	0.6 %	
Isotope ratio standard	Gravimetric mixing (from cross-check of independent sets of calibration standard mixtures)	0.5 %	Included in reproducibility
Weight of sample taken for extraction	Readability and linearity of the balance (from the certificate of the balance)	< 0.01 %	
Weight of sample extract taken for analysis	Readability and linearity of the balance (from the certificate of the balance)	< 0.01 %	Included in repeatability within a time period
Weight of glucosamine-1- <sup>13</sup> C standard solution spiked into sample extract	Readability and linearity of the balance (from the certificate of the balance)	< 0.01 %	
Peak area ratio of glucosamine and glucosamine-1- <sup>13</sup> C from isotope ratio standard	Standard deviation of multiple measurements (typically from 4 runs)	0.4 %	
Peak area ratio of glucosamine and glucosamine-1- <sup>13</sup> C of sample extract	Standard deviation of multiple measurements (typically from 4 runs)	0.4 %	

<sup>a</sup>Relationships of each uncertainty sources with the repeatability and the reproducibility are based on the measurement protocol used in this study.

method in SIM mode are listed in Table 3. In the table, uncertainty sources are categorized according to their effects to repeatability and reproducibility test with following the measurement protocol described above. The expanded uncertainty in 95 % confidence level is less than 4 % as shown in Table 1, indicating that the method has a high metrological quality as a reference method.

### Conclusions

An isotope dilution mass spectrometric method based on a flow-injection ESI/MS has been established and evaluated as a candidate reference method for the analysis of glucosamine in pharmaceutical products. The repeatability and reproducibility test results proved that the method provides a high metrological quality as a reference method. The candidate reference method will be used later in our laboratory for the certification of glucosamine in food supplemental reference materials.

### References

1. Liang, Z.; Leslie, J.; Adebawale, A.; Ashraf, M.; Eddington, N. D. *J. Pharm. Biomed. Anal.* **1999**, *20*, 807.
2. Shao, Y.; Alluri, R.; Mummert, M.; Koetter, U.; Lech, S. *J. Pharm. Biomed. Anal.* **2004**, *35*, 625.
3. Felson, D. T.; Zhang, Y. *Arthritis. Rheum.* **1998**, *41*, 1343.
4. Uebelhart, D.; Thonar, E. J.-M.; Zhang, J.; Williams, J. M. *Osteoarthritis. Cartilage.* **1998**, *6 (Supplement A)*, 6.
5. Wu, Y.; Hussain, M.; Fassihi, R. *J. Pharm. Biomed. Anal.* **2005**, *38*, 263.
6. Zhu, X.; Cai, J.; Yang, J.; Su, Q. *Carbohydr. Research* **2005**, *340*, 1732.
7. El-Saharty, Y. S.; Bary, A. A. *Anal. Chim. Acta* **2002**, *462*, 125.
8. Crespo, M. O. P.; Martínez, M. V.; Hernández, J. L.; Yusty, M. A. L. *J. Chromatogr. A* **2006**, *1116*, 189.
9. Huang, T.-M.; Cai, L.; Yang, B.; Zhou, M.-X.; Shen, Y.-F.; Duan, G.-L. *Biomed. Chromatogr.* **2006**, *20*, 215.
10. Huang, T.-M.; Deng, C.-H.; Chen, N.-Z.; Liu, Z.; Duan, G.-L. *J. Sep. Sci.* **2006**, *29*, 2296.
11. Tekko, I. A.; Bonner, M. C.; Williams, A. C. *J. Pharm. Biomed. Anal.* **2006**, *41*, 385.
12. Roda, A.; Sabatini, L.; Barbieri, A.; Guardigli, M.; Locatelli, M.; Violante, F. S.; Rovati, L. C.; Persiani, S. *J. Chromatogr. B* **2006**, *844*, 119.
13. Kim, B.; Kim, D. H.; Choi, J. O.; So, H.-Y. *Bull. Korean Chem. Soc.* **1999**, *20*, 910.
14. Jung, M.; Kim, B.; Boo, D. W.; So, H.-Y. *Bull. Korean Chem. Soc.* **2007**, *28*, 745.
15. Park, S.; Kim, B.; So, H.-Y.; Kim, Y.-J.; Kim, J. *Bull. Korean Chem. Soc.* **2007**, *28*, 737.
16. Jung, P. G.; Kim, B.; Park, S.-R.; So, H.-Y.; Shi, L. H.; Kim, Y. *Anal. Bioanal. Chem.* **2004**, *380*, 782.